VistaGen Therapeutics
VTGN
20 hedge funds and large institutions have $2.02M invested in VistaGen Therapeutics in 2018 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 6 closing their positions.
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
18% more funds holding
Funds holding: 17 → 20 (+3)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.4% less ownership
Funds ownership: 0.72% → 0.32% (-0.4%)
61% less capital invested
Capital invested by funds: $5.23M → $2.02M (-$3.21M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
Top Sellers
VTGN Hedge Fund Activity: Q1 2018 in Review
20 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q1 2018, worth a combined $2.02M — down 61% from $5.23M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new VTGN positions and 6 closed out — a net gain of 3 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Ibex Investors, opening a new position worth an estimated $223K. The largest seller was Sabby Management, cutting an estimated $2.44M.
- 20 institutional investors held VistaGen Therapeutics (VTGN) as of Q1 2018, up from 17 in Q4 2017.
- Funds reported $2.02M of VistaGen Therapeutics stock for Q1 2018, down 61% quarter-over-quarter.
- 9 funds opened new VistaGen Therapeutics positions in Q1 2018 and 6 closed out, a net change of +3 holders.
- The largest VistaGen Therapeutics buyer in Q1 2018 was Ibex Investors, an estimated $223K added.
- The largest VistaGen Therapeutics seller in Q1 2018 was Sabby Management, an estimated $2.44M sold.
Based on aggregated 13F filings for Q1 2018.